Just a year out of the gate, Atlas Venture-backed Spero Therapeutics LLC snagged Roche AG as a partner to develop anti-infectives for drug-resistant bacterial infections, targeting a pathway that involves both virulence and persistence of gram-negative bacteria such as Pseudomonas aeruginosa (P. aeruginosa).